Crossmark

Immunomodulation for primary prevention of urinary tract infections in patients with spinal cord injury during primary rehabilitation: protocol for a randomized placebo-controlled pilot trial (UROVAXOM-pilot)

Crossref DOI link: https://doi.org/10.1186/s13063-021-05630-w

Published Online: 2021-10-04

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Krebs, Jörg https://orcid.org/0000-0003-1807-2670
Stoyanov, Jivko

Wöllner, Jens

Valido, Ezra

Pannek, Jürgen
Funding

Funding for this research was provided by:

Swiss Paraplegic Foundation
License Information

Text and Data Mining valid from 2021-10-04

Version of Record valid from 2021-10-04
More Information

Article History

Received: 27 November 2020

Accepted: 15 September 2021

First Online: 4 October 2021

Declarations

:

: The Ethics Committee of Northwestern and Central Switzerland has approved the present trial protocol (ID 2019-01768, final approval 26.11.2019). Written informed consent to participate will be obtained from all participants.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below